ActualSignal

ActualSignal operates at the intersection of digital health, neurological monitoring, medical software, and artificial intelligence. Its focus is narrower than general-purpose remote patient monitoring platforms: the core use case is Parkinson’s disease and related movement-disorder assessment, with finger-tapping videos and activity data serving as key inputs. The company’s stated differentiation is an everyday smartphone workflow that can collect longitudinal observations without additional devices, potentially reducing equipment and access barriers for patients. Its December 2024 seed round and single-investor profile indicate initial external backing, while the small employee range suggests that product development and clinical validation remain central priorities.

ActualSignal was founded in 2022 and recorded one seed round on December 1, 2024, with RUNI Ventures identified as the investor. The financing amount is undisclosed, so capital-based growth cannot be quantified. The company’s product trajectory centers on moving neurological monitoring beyond episodic clinic visits: its ActualSignal App uses smartphone finger-tapping videos, activity information, and patient-reported outcomes to create a continuing view of Parkinson’s symptoms. This represents a meaningful product inflection point because it combines passive or lightweight data collection with structured patient check-ins and clinician review. As of October 7, 2026, the evidence supports a trajectory from founding and initial product development to seed-backed commercialization or validation efforts, but not yet to demonstrated large-scale adoption. Further indicators to watch include clinical evidence, healthcare partnerships, regulatory progress, and subsequent financing.